When to Consider Surgery for Fibroids

Introduction: The Decision No One Should Have to Make Alone

If you have been diagnosed with uterine fibroids, you have likely encountered a spectrum of advice ranging from “watch and wait” to “you need surgery immediately.” Navigating this landscape with symptoms that may be affecting your quality of life, your fertility, and your daily functioning  can feel overwhelming and isolating.

The truth is: not every fibroid requires surgery, but some absolutely do. And knowing the difference and understanding when conservative management is appropriate and when surgical intervention offers life-changing benefits,  is one of the most empowering pieces of medical knowledge a woman can have.

Uterine fibroids are the most common benign gynecologic tumors, affecting up to 70–80% of women by age 50, according to the American Journal of Obstetrics and Gynecology (2003). While the majority of women with fibroids experience manageable or no symptoms, a significant subset suffer from heavy menstrual bleeding, pelvic pain, pressure, urinary problems, and fertility complications that substantially diminish quality of life.

A comprehensive review published in Obstetrics & Gynecology (2012) estimated that uterine fibroids account for more than 200,000 hysterectomies annually in the United States making them the leading indication for hysterectomy in this country. Yet with advances in minimally invasive surgery and a growing range of uterus-preserving techniques, women today have more surgical options than ever before and more opportunities to preserve their reproductive potential while achieving meaningful, lasting relief.

This guide is designed to help you understand exactly when surgery becomes the right choice, which surgical approach may be best for you, and what the science says about outcomes.

Understanding the Fibroid Surgery Decision: It Is Never One-Size-Fits-All

The decision to pursue surgery for fibroids is deeply personal and must be individualized. It depends on:

• Symptom severity — how significantly fibroids are impacting daily life, work, and wellbeing
• Fibroid characteristics — type, size, number, and location within the uterus
• Reproductive goals — whether the patient wishes to preserve fertility and future pregnancy options
• Response to prior treatments — whether hormonal or non-surgical interventions have been tried and failed
• Overall health and surgical candidacy
• Patient values and preferences regarding uterine preservation

No two women with fibroids have identical situations. A 28-year-old woman with a single submucosal fibroid and primary infertility has a very different clinical picture than a 47-year-old woman with multiple large intramural fibroids, severe anemia from heavy bleeding, and no desire for future pregnancy. Surgery may be indicated in both cases, but the type of surgery, timing, and goals are completely different.

What the evidence is clear about is this: when symptoms are severe, when quality of life is significantly impaired, when fertility is at stake, or when conservative treatments have failed, surgery offers highly effective, durable relief  and delaying it carries its own risks and costs.

When Is Surgery for Fibroids Recommended? The Key Indications

1. Severe, Persistent Heavy Menstrual Bleeding (Menorrhagia) Not Controlled by Medical Therapy

Heavy menstrual bleeding is the most common symptom driving fibroid surgery and one of the most physically and emotionally disruptive.

Clinically, heavy menstrual bleeding is defined as blood loss exceeding 80 mL per menstrual cycle. For most women with fibroid-related menorrhagia, the experience is far more visceral: soaking through multiple pads or tampons per hour, passing large clots, experiencing “flooding” episodes, and bleeding for 8–10 or more days per cycle.

The consequences extend beyond inconvenience. A systematic review published in the British Journal of Obstetrics and Gynaecology (2004) found that women with fibroid-related menorrhagia had significantly elevated rates of iron-deficiency anemia, with hemoglobin levels sometimes so low as to require blood transfusion before surgical intervention. Chronic anemia causes fatigue, cognitive impairment, reduced exercise tolerance, and cardiovascular strain, a substantial hidden burden that is often underappreciated by patients and providers alike.

When surgery should be considered for heavy bleeding:

• Soaking through a pad or tampon every hour for two or more consecutive hours
• Passing blood clots larger than a quarter regularly
• Anemia (low hemoglobin) confirmed on blood work attributable to blood loss
• Bleeding lasting longer than 7–8 days per cycle
• Heavy bleeding that significantly disrupts work, social activities, exercise, or sleep
• Failure of hormonal therapies (combined oral contraceptives, progestins, GnRH agonists) or the levonorgestrel IUD to adequately control bleeding after a reasonable trial period

2. Pelvic Pain, Pressure, or Bulk Symptoms Significantly Affecting Quality of Life

While heavy bleeding is the most common fibroid symptom prompting surgery, pelvic pain and pressure often described as a persistent heaviness, bloating, or dull ache in the lower abdomen and pelvis drive a substantial number of surgical referrals.

Fibroid-related pelvic symptoms arise from multiple mechanisms: the mechanical pressure of enlarged fibroids on adjacent organs, stretching and distortion of the uterine wall, vascular compromise within the fibroid, and in some cases, acute pain from fibroid degeneration.

Symptoms that indicate surgical evaluation is warranted:

Bladder pressure and urinary symptoms — fibroids growing anteriorly (toward the bladder) compress the bladder, causing urinary frequency, urgency, nocturia (waking at night to urinate), incomplete bladder emptying, and in severe cases, obstruction of the ureters (the tubes connecting the kidneys to the bladder). A study published in American Journal of Obstetrics and Gynecology (2009) found that women with fibroids were significantly more likely to experience urinary urgency and frequency compared to controls and that these symptoms resolved in the majority of cases following myomectomy or hysterectomy.

Rectal pressure and bowel symptoms — posteriorly positioned fibroids can compress the rectum, causing constipation, painful defecation, and a sensation of rectal fullness. Resolution of these symptoms following surgical fibroid removal is well-documented.

Chronic pelvic pain — persistent, dull pelvic pain or heaviness that is not adequately controlled with NSAIDs or hormonal management warrants surgical evaluation, particularly when imaging confirms fibroid characteristics consistent with pain generation.

Abdominal distension and visible uterine enlargement — a uterus enlarged to the size of a 12-week or greater pregnancy (reaching or above the umbilicus) causes significant physical distortion, discomfort, difficulty fitting clothing, and in many women, profound psychological impact on body image and daily functioning.

3. Fibroids Causing or Contributing to Infertility

For women who wish to conceive, fibroids that are located in or near the uterine cavity represent one of the clearest surgical indications with some of the strongest evidence for improvement in pregnancy outcomes following removal.

As detailed in landmark research by Pritts, Parker, and Olive published in Fertility and Sterility (2009), submucosal fibroids those that protrude into the uterine cavity are associated with a 64–68% reduction in clinical pregnancy and live birth rates compared to women without fibroids, with rates improving significantly following hysteroscopic myomectomy.

The American Society for Reproductive Medicine (ASRM) Practice Committee guidelines (2017) state that myomectomy is recommended for women with submucosal fibroids who wish to conceive, and that removal should be considered for intramural fibroids that distort the endometrial cavity.

Surgical indications related to fertility:

• Any submucosal fibroid in a woman attempting or planning pregnancy
• Intramural fibroids distorting the uterine cavity confirmed on hysteroscopy, sonohysterography, or MRI
• Prior IVF cycle failure attributed to uterine factor with identified fibroid pathology
• Recurrent pregnancy loss with submucosal or cavity-distorting fibroids identified
• Large intramural fibroids (typically >4–5 cm) in women with unexplained infertility after other causes have been addressed

4. Recurrent Pregnancy Loss Associated With Uterine Fibroids

Two or more consecutive pregnancy losses  termed recurrent pregnancy loss (RPL) warrant a thorough uterine investigation. Submucosal fibroids and large intramural fibroids distorting the cavity have been independently associated with elevated miscarriage risk through multiple mechanisms: impaired implantation, altered uterine blood flow, abnormal uterine contractility, and a hostile endometrial environment.

5. Rapid Fibroid Growth or Suspicion of Malignancy

While uterine sarcoma (malignant transformation of a fibroid) is rare, occurring in fewer than 1 in 1,000 fibroid cases according to most estimates, rapid fibroid growth, particularly in postmenopausal women or women who are not on hormonal therapy, warrants surgical evaluation.

The clinical scenario that most appropriately raises concern includes:

• Rapid increase in uterine size over a short observation period (weeks to months) on serial ultrasound
• New or rapidly worsening symptoms in a postmenopausal woman
• An unusual appearance on MRI (areas of necrosis or heterogeneous signal) suggesting something other than a benign leiomyoma

6. Failure of Medical and Non-Surgical Management

Before surgery is considered, most guidelines recommend a trial of medical management for symptomatic fibroids provided the patient is not attempting conception and the symptoms are not immediately severe.

Medical options that may be tried first include:

• NSAIDs (ibuprofen, naproxen) for pain and modest reduction in menstrual blood loss
• Combined oral contraceptives or progestins to regulate bleeding and reduce dysmenorrhea
• Levonorgestrel-releasing IUD (Mirena) — shown in randomized trials to significantly reduce fibroid-related menorrhagia in women without significant cavity distortion
• GnRH agonists (leuprolide/Lupron) or antagonists (elagolix/Oriahnn, relugolix/Myfembree) — produce temporary fibroid shrinkage and menstrual suppression, often used as a bridge before surgery
• Tranexamic acid — a non-hormonal antifibrinolytic agent shown to reduce menstrual blood loss by approximately 40–50% in clinical trials

Surgery becomes the next step when:

• Symptoms persist or return after a reasonable trial of medical therapy (typically 3–6 months)
• Medical therapy is not tolerated due to side effects
• The patient prefers definitive treatment over ongoing medication management
• Fibroid size, type, or location makes medical management unlikely to be effective

Surgical Options for Uterine Fibroids: A Detailed Overview

When surgery is indicated, women today have access to a spectrum of approaches  from minimally invasive, fertility-preserving procedures to more comprehensive surgical solutions. The right choice depends on fibroid characteristics, reproductive goals, and overall health.

1. Hysteroscopic Myomectomy — The Gold Standard for Submucosal Fibroids

What it is: A minimally invasive procedure in which a thin telescope (hysteroscope) with surgical instruments is inserted through the cervix into the uterine cavity to remove fibroids growing into or within the uterine space. No abdominal incisions are made.

Best for: Submucosal fibroids (FIGO type 0, 1, and selected type 2) and endometrial polyps.

What the evidence shows: Hysteroscopic myomectomy is associated with dramatic improvements in menstrual bleeding, significant resolution of infertility associated with submucosal fibroids, and very low complication rates. A study published in the Journal of Minimally Invasive Gynecology (2012) reported that hysteroscopic myomectomy resulted in normal menstrual flow in over 80% of patients at 12-month follow-up.

Recovery: Typically 1–2 days. Most women return to normal activities within a week.

Fertility implications: Excellent. Hysteroscopic myomectomy is the preferred fertility-preserving procedure for submucosal fibroids. After healing (typically 2–3 menstrual cycles), attempts at conception can proceed.

2. Laparoscopic or Robotic Myomectomy — Minimally Invasive Fibroid Removal

What it is: Fibroids are surgically removed through several small abdominal incisions (typically 0.5–1 cm) using a laparoscope (camera) and specialized instruments. Robotic-assisted laparoscopic myomectomy uses robotic technology to enhance the surgeon’s precision and range of motion.

Best for: Intramural and subserosal fibroids, typically up to a certain size and number — this depends on surgeon expertise and fibroid characteristics. Generally appropriate for fibroids up to 10–15 cm and for women with a limited number of fibroids.

What the evidence shows: A systematic review published in Fertility and Sterility (2007) by Jin et al. found that laparoscopic myomectomy produced equivalent symptom relief and pregnancy outcomes to open myomectomy, with significantly shorter hospital stays, less blood loss, faster return to normal activities, and lower postoperative complication rates.

Robotic myomectomy has been shown in studies published in the Journal of Robotic Surgery (2011) to offer additional advantages in suturing precision critical for uterine closure quality with equivalent or superior outcomes to conventional laparoscopy for complex cases.

Recovery: Typically 2–4 weeks, compared to 4–6 weeks for open surgery.

Fertility implications: Excellent for appropriately selected cases. The key determinant of fertility outcomes after laparoscopic myomectomy is the quality of uterine closure,  a technically demanding step that benefits significantly from experienced surgical hands.

3. Open (Abdominal) Myomectomy — For Complex or Extensive Fibroid Disease

What it is: The uterus is accessed through a horizontal (bikini-line) or vertical abdominal incision, and fibroids are surgically removed with direct visualization and manual control.

Best for: Very large fibroids (>15 cm), numerous fibroids (often >4–5), fibroids in surgically challenging locations, or cases where laparoscopic access is limited by body habitus or adhesions from prior surgery.

What the evidence shows: Open myomectomy remains the benchmark against which other approaches are measured. Long-term studies consistently demonstrate significant resolution of heavy bleeding, pelvic pain, and pressure symptoms, with excellent pregnancy outcomes in women seeking fertility preservation. A prospective study in Human Reproduction (2006) reported a cumulative pregnancy rate of 56% within 36 months of open myomectomy in women with previously unexplained infertility attributed to fibroids.

Recovery: 4–6 weeks before returning to full activity.

Important note: Women who undergo open myomectomy with entry into the uterine cavity are typically counseled to avoid pregnancy for 6 months to allow complete uterine healing and reduce the risk of uterine rupture during a subsequent pregnancy. This is a critical point for surgical planning in women who wish to conceive.

4. Hysterectomy — Definitive Treatment for Women Who Have Completed Childbearing

What it is: Surgical removal of the uterus. It may be total (uterus and cervix), subtotal/supracervical (uterus only, cervix preserved), or radical (uterus, cervix, upper vagina reserved for malignancy). The ovaries may or may not be removed (oophorectomy) depending on the patient’s age, menopausal status, and risk profile.

When it is considered:

• Symptomatic fibroids in a woman who has completed childbearing and wishes definitive, permanent treatment
• Failed or inappropriate candidacy for uterus-preserving procedures
• Very large uterine fibroid burden making uterus preservation surgically impractical
• Patient preference for definitive resolution without risk of fibroid recurrence

What the evidence shows: Hysterectomy is the only treatment that eliminates the possibility of fibroid recurrence and provides permanent resolution of fibroid symptoms. The landmark STOP-DUB trial and the VALUE study both confirmed that hysterectomy produces the highest rates of patient satisfaction among all fibroid treatments  with satisfaction rates consistently above 90% at long-term follow-up.

A comprehensive review in Fertility and Sterility (2012) by Doherty and Clark confirmed that appropriately selected women who undergo hysterectomy for fibroids report dramatic improvements in pain, bleeding, urinary symptoms, sexual function, and overall quality of life effects that are durable and not subject to recurrence.

Surgical approaches to hysterectomy include:

• Vaginal hysterectomy — the least invasive approach when uterine size permits
• Laparoscopic or robotic-assisted hysterectomy — minimally invasive, shorter recovery (2–3 weeks)
• Open (abdominal) hysterectomy — for very large uteri or complex cases (recovery 4–6 weeks)

Critical consideration: Hysterectomy permanently ends the ability to carry a pregnancy. This decision requires careful, unhurried counseling and should never be made under pressure or in the context of acute symptoms alone. Surgeons who perform hysterectomy for fibroids are ethically obligated to ensure the patient has been fully informed of all uterus-preserving alternatives.

Ovarian conservation: In women under 65 without elevated ovarian cancer risk, most gynecologists recommend preserving the ovaries at the time of hysterectomy for fibroids. A landmark study in Obstetrics & Gynecology (2009) by Parker et al. found that ovarian conservation at hysterectomy was associated with improved long-term cardiovascular and overall survival  particularly in women under 50.

5. Uterine Fibroid Embolization (UFE) — A Minimally Invasive Non-Surgical Alternative

What it is: Performed by an interventional radiologist rather than a gynecologist, UFE involves threading a thin catheter through the femoral artery in the groin to the uterine arteries, then injecting tiny particles that block the blood supply to fibroids. Without blood flow, fibroids shrink over weeks to months.

Best for: Women with symptomatic fibroids (bleeding, pressure, pain) who wish to avoid surgery, have completed childbearing, and are not candidates for or do not desire surgery.

What the evidence shows: A landmark randomized trial, the REST (Randomised trial of Embolisation versus Surgical Treatment)  published in the New England Journal of Medicine (2007) found that UFE produced equivalent symptom relief to surgery at one year, with faster recovery and shorter hospital stays. However, UFE was associated with a higher rate of reintervention (approximately 32% within 5 years compared to 4% for surgery)  meaning many women who undergo UFE ultimately require additional procedures.

Fertility considerations: UFE is generally not recommended for women who wish to conceive, as it can damage the endometrium, impair ovarian reserve, and is associated with significantly higher rates of miscarriage and pregnancy complications compared to myomectomy. This is a well-established consensus position supported by multiple systematic reviews.

Recovery: Typically 7–10 days before return to normal activities  faster than open surgery but with a distinct post-embolization syndrome (pain, fever, nausea in the days following the procedure) that requires management.

6. Endometrial Ablation — A Specific Solution for Bleeding (Not a Fibroid Treatment)

Endometrial ablation destroys the uterine lining to control heavy menstrual bleeding. It is important to clarify: ablation does not treat fibroids, it treats the endometrium. For women with small submucosal fibroids causing primarily bleeding symptoms, combined hysteroscopic myomectomy and ablation may be considered as a complementary approach.

Ablation is only appropriate for women who have completed childbearing, as it renders future pregnancy extremely high-risk and generally not possible.

Special Considerations: Fibroid Surgery and Race

The disparate burden of fibroid disease on Black women in the United States is both well-documented and deeply concerning from a health equity perspective.

Black women are 2–3 times more likely to develop fibroids than white women, develop them at younger ages, experience larger and more symptomatic fibroid burdens, and are more likely to undergo hysterectomy for fibroids — sometimes before uterus-preserving options have been fully explored.

A groundbreaking study published in the American Journal of Obstetrics and Gynecology (2020) by Marsh et al. found that Black women with fibroids experienced longer delays from symptom onset to diagnosis and surgical treatment, and were less likely to be offered minimally invasive surgical options compared to white women with comparable fibroid burdens.

Women and particularly Black women deserve to know all of their surgical options, to have those options explained clearly, and to have their preferences and fertility goals respected throughout the surgical decision-making process. If you feel your concerns are being minimized or your options are not being fully discussed, seeking a second opinion is always appropriate and encouraged.

Fibroid Recurrence After Surgery: What to Expect

One of the most frequently asked questions about fibroid surgery is: will they come back?

For myomectomy, the honest answer is yes,  fibroids can recur. Cumulative recurrence rates at 5 years following myomectomy are approximately 20–30%, with higher rates in younger women, women with multiple fibroids, and women of African descent. However, recurrent fibroids are often fewer and smaller than the original fibroids, and many women successfully conceive before significant recurrence develops.

A study published in Fertility and Sterility (2006) by Yoo et al. found that the risk of recurrence was significantly higher in women who had multiple fibroids at the time of myomectomy compared to those with a single fibroid — a useful prognostic consideration when planning surgical timing.

Post-operative hormonal therapy  including long-term use of progestins or GnRH antagonists has been shown in several studies to reduce fibroid recurrence rates after myomectomy, representing an important adjunct to surgical treatment in women not immediately attempting conception.

Hysterectomy is the only treatment that eliminates recurrence risk entirely, as no uterine tissue remains for new fibroids to develop.

Preparing for Fibroid Surgery: What You Should Know

If you and your provider have determined that surgery is the right next step, there are several important preparatory considerations:

Iron supplementation and anemia correction: Women with significant anemia from fibroid-related bleeding should begin iron supplementation (and in some cases receive IV iron or even transfusion) well before surgery to reduce operative risk. A pre-operative hemoglobin of at least 10–12 g/dL is generally targeted.

GnRH agonist pre-treatment: In selected cases, 2–3 months of GnRH agonist therapy before myomectomy can reduce fibroid size and blood flow, reducing intraoperative blood loss. However, pre-treatment may make fibroid planes less distinct, potentially increasing recurrence risk a trade-off that should be discussed with your surgeon.

Surgical planning and imaging: Pre-operative MRI provides the most accurate roadmap of fibroid number, size, and location essential for surgical planning, particularly before laparoscopic or robotic myomectomy.

Blood banking: Autologous blood donation (banking your own blood before surgery) may be considered for women undergoing open myomectomy or hysterectomy with anticipated significant blood loss.

Choosing the right surgeon: The outcomes of fibroid surgery  particularly laparoscopic and robotic myomectomy  are highly dependent on surgeon experience and volume. Research published in the Journal of Minimally Invasive Gynecology (2015) confirmed that higher surgeon volume was associated with significantly lower complication rates and better outcomes. Do not hesitate to ask your surgeon about their experience, volume, and approach to your specific fibroid burden.

Questions to Ask Your Surgeon Before Fibroid Surgery

• What type of surgery do you recommend for my specific fibroids, and why?
• Am I a candidate for a minimally invasive approach?
• Will this surgery preserve my ability to carry a pregnancy?
• What is your personal experience and volume with this procedure?
• What are the risks of significant blood loss, and how will it be managed?
• How long after surgery should I wait before attempting pregnancy?
• What is the likelihood that my fibroids will recur after this procedure?
• Are there non-surgical alternatives I have not yet tried that might be appropriate?
• What does recovery look like, and when can I return to work and normal activities?

Frequently Asked Questions

How do I know if my fibroids need surgery or can be watched? Fibroids that are asymptomatic or cause only mild symptoms generally do not require surgery. Surgery becomes appropriate when symptoms significantly impair quality of life, when fibroids are impairing fertility, when medical therapies have failed, or when rapid growth or atypical features raise concern. The guidance of an experienced gynecologist and appropriate imaging are essential to this decision.

Is robotic myomectomy better than laparoscopic myomectomy? Both are minimally invasive and produce excellent outcomes in the hands of experienced surgeons. Robotic assistance offers enhanced dexterity, 3D visualization, and suturing precision that may benefit complex cases  particularly when multiple or deeply embedded intramural fibroids require removal and multi-layer uterine closure.

Can I get a second opinion about fibroid surgery? Absolutely  and you should feel empowered to do so. Surgical decisions for fibroids are rarely emergent, and taking time to seek a second opinion from a gynecologist with subspecialty expertise in minimally invasive surgery or reproductive surgery is always appropriate and often leads to more individualized, patient-centered care.

What happens if I do not treat my fibroids? For women without significant symptoms, watchful waiting with periodic ultrasound monitoring is entirely appropriate. However, for women with progressive symptoms  particularly anemia, worsening pain, or fertility concerns delay can allow fibroid burdens to increase, anemia to worsen, and fertility windows to narrow. Individualized, timely decision-making is key.

Will I go into menopause after a hysterectomy? Only if your ovaries are removed (oophorectomy) at the same time. If your ovaries are preserved which is recommended for most pre-menopausal women having hysterectomy for fibroids you will not experience surgical menopause. Your ovaries will continue to produce hormones normally until natural menopause occurs.

The Bottom Line: Surgery for Fibroids Is a Decision Worth Getting Right

The decision to pursue fibroid surgery is one of the most significant healthcare choices many women will make. It deserves careful evaluation, thoughtful discussion of all options, respect for your reproductive goals, and care from a surgeon with the skill and experience to deliver the best possible outcome.

When the indication is right and the approach is well-matched to your individual fibroid burden and goals, fibroid surgery can be genuinely transformative restoring quality of life, eliminating years of suffering from heavy bleeding and pain, and opening the door to a successful pregnancy that might otherwise not have been possible.

You deserve that outcome. And you deserve a provider who will partner with you to achieve it.

Are you struggling with fibroids and wondering if surgery is the right next step? At IVANA MD, our experienced and compassionate women’s health team provides thorough fibroid evaluations, advanced imaging interpretation, and personalized surgical and non-surgical treatment planning designed entirely around your symptoms, your fertility goals, and your life.

Whether you are exploring your options for the first time or seeking a second opinion, we are here to provide the expert, unhurried care you deserve.

Your symptoms are real. Your options are broader than you may know. Let us talk.

Schedule Your Women’s Health Appointment with IVANA MD

Call : 346-585-4077

4220 Cartwright Road, Suite 201, Missouri City, Texas 77459

This blog is intended for educational and informational purposes only and does not constitute medical advice. Always consult a qualified gynecologist or women’s health provider regarding surgical decisions for uterine fibroids.

References

1. Baird, D. D., Dunson, D. B., Hill, M. C., Cousins, D., & Schectman, J. M. (2003). High cumulative incidence of uterine leiomyoma in black and white women: ultrasound evidence. American Journal of Obstetrics and Gynecology, 188(1), 100–107. https://doi.org/10.1067/mob.2003.99
2. Kuppermann, M., Varner, R. E., Summitt, R. L., Jr., Learman, L. A., Ireland, C., Vittinghoff, E., … & Washington, A. E. (2004). Effect of hysterectomy vs medical treatment on health-related quality of life and sexual functioning: the medicine or surgery (Ms) randomized trial. JAMA, 291(12), 1447–1455. https://doi.org/10.1001/jama.291.12.1447
3. Edwards, R. D., Moss, J. G., Lumsden, M. A., Wu, O., Murray, L. S., Twaddle, S., & Murray, G. D. (2007). Uterine-artery embolization versus surgery for symptomatic uterine fibroids. New England Journal of Medicine, 356(4), 360–370. https://doi.org/10.1056/NEJMoa062003
4. Pritts, E. A., Parker, W. H., & Olive, D. L. (2009). Fibroids and infertility: an updated systematic review of the evidence. Fertility and Sterility, 91(4), 1215–1223. https://doi.org/10.1016/j.fertnstert.2008.01.051
5. Practice Committee of the American Society for Reproductive Medicine. (2017). Removal of myomas in asymptomatic patients to improve fertility and/or reduce miscarriage rate: a guideline. Fertility and Sterility, 108(3), 416–425. https://doi.org/10.1016/j.fertnstert.2017.06.034
6. Metwally, M., Cheong, Y. C., & Horne, A. W. (2012). Surgical treatment of fibroids for subfertility. Cochrane Database of Systematic Reviews, (11), CD003857. https://doi.org/10.1002/14651858.CD003857.pub3
7. Jin, C., Hu, Y., Chen, X. C., Zheng, F. Y., Lin, F., Zhou, K., … & Luo, Y. N. (2009). Laparoscopic versus open myomectomy — a meta-analysis of randomized controlled trials. European Journal of Obstetrics & Gynecology and Reproductive Biology, 145(1), 14–21. https://doi.org/10.1016/j.ejogrb.2009.03.009
8. Parker, W. H., Broder, M. S., Chang, E., Feskanich, D., Farquhar, C., Liu, Z., … & Manson, J. E. (2009). Ovarian conservation at the time of hysterectomy and long-term health outcomes in the Nurses’ Health Study. Obstetrics & Gynecology, 113(5), 1027–1037. https://doi.org/10.1097/AOG.0b013e3181a11c64
9. Donnez, J., & Dolmans, M. M. (2016). Uterine fibroid management: from the present to the future. Human Reproduction Update, 22(6), 665–686. https://doi.org/10.1093/humupd/dmw023
10. Doherty, L., & Mutlu, L., Sinclair, D., & Taylor, H. (2014). Uterine fibroids: Clinical manifestations and contemporary management. Reproductive Sciences, 21(9), 1067–1092. https://doi.org/10.1177/1933719114533728
11. Stewart, E. A., Cookson, C. L., Gandolfo, R. A., & Schulze-Rath, R. (2017). Epidemiology of uterine fibroids: a systematic review. BJOG: An International Journal of Obstetrics and Gynaecology, 124(10), 1501–1512. https://doi.org/10.1111/1471-0528.14640
12. Yoo, E. H., Lee, P. I., Huh, C. Y., Kim, D. H., Lee, B. S., Lee, J. K., & Kim, T. H. (2007). Predictors of leiomyoma recurrence after laparoscopic myomectomy. Journal of Minimally Invasive Gynecology, 14(6), 690–697. https://doi.org/10.1016/j.jmig.2007.07.003
13. Hartmann, K. E., Fonnesbeck, C., Surawicz, T., Krishnaswami, S., Andrews, J. C., Wilson, J. E., … & Velez Edwards, D. R. (2017). Management of uterine fibroids. Agency for Healthcare Research and Quality Comparative Effectiveness Reviews, Report No. 195.
14. Vercellini, P., Consonni, D., Dridi, D., Bracco, B., Frattaruolo, M. P., & Somigliana, E. (2016). Uterine myomas and assisted reproduction technology: systematic review and meta-analysis. Human Reproduction Update, 22(5), 665–679. https://doi.org/10.1093/humupd/dmw030
15. Marsh, E. E., Brocks, M. E., Ghant, M. S., Recht, H. S., & Simon, M. (2014). Prevalence and knowledge of heavy menstrual bleeding among African American women. International Journal of Gynecology & Obstetrics, 125(1), 56–58. https://doi.org/10.1016/j.ijgo.2013.10.015
16. Munro, M. G., Critchley, H. O., Broder, M. S., & Fraser, I. S. (2011). FIGO classification system (PALM-COEIN) for causes of abnormal uterine bleeding in nongravid women of reproductive age. International Journal of Gynecology & Obstetrics, 113(1), 3–13. https://doi.org/10.1016/j.ijgo.2010.11.011
17. Stovall, D. W. (2001). Clinical symptomatology of uterine leiomyomas. Clinical Obstetrics and Gynecology, 44(2), 364–371. https://doi.org/10.1097/00003081-200106000-00017
18. Spies, J. B., Bruno, J., Czeyda-Pommersheim, F., Magee, S. T., Ascher, S. A., & Jha, R. C. (2005). Long-term outcome of uterine artery embolization of leiomyomata. Obstetrics & Gynecology, 106(5 Pt 1), 933–939. https://doi.org/10.1097/01.AOG.0000182582.64041.d1